Compare Abbott Laboratories (ABT) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Expeditors International of Wshngtn Inc — how do they compare? Abbott Laboratories trades at $94.95 (market cap $166.94B), while Expeditors International of Wshngtn Inc trades at $165.19 (market cap $21.68B). The key difference: Abbott Laboratories is far larger — about 7.7× Expeditors International of Wshngtn Inc's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | EXPD | |
|---|---|---|
Market Cap | $166.94B | $21.68B |
Sector | Health | Industrials |
52-Week High | $136.62 | $167.57 |
52-Week Low | $82.57 | $111.37 |
Enterprise Value | $193.69B | $20.93B |
Dividend Yield | 2.63% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
EXPD trades at $165.74, down 1.09% today, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company shows consistent earnings beats, with Q1 2026 EPS of $1.71 surpassing expectations of $1.33. Revenue growth is steady, reaching $11.07B in 2025, while maintaining robust profitability with a net margin of 7.48% and ROE of 36.59%. Recent news highlights EXPD's resilience in transportation services amid industry challenges.
The stock presents a mixed outlook: strong fundamentals and technical momentum support upside potential, but valuation multiples like P/E of 26.77 suggest premium pricing. Risks include economic sensitivity and competitive pressures. Analyst consensus is cautious with 60.61% hold ratings, though price targets indicate limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
